Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosigotifator for Single-Patient Treatment of Cree Leukoencephalopathy
NCT07272525Phase 1Active, not recruiting
- Sponsor
- McGill University Health Centre
- Start
- Nov 2024
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fosigotifator in Cree leukoencephalopathy (CLE), sponsored by McGill University Health Centre. Primary endpoint: Patient survival or need for continuous ventilatory support at 3 years. Started Nov 2024; status: active, not recruiting.
02
Drugs
fosigotifator
03
Conditions
Cree leukoencephalopathy (CLE)
Beyond the preview
Go deeper on NCT07272525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07272525.